New CMDh Q&A Document on the Implementation of the EU Falsified Medicines Directive
Recommendation
Tuesday, 8 June 2027 13.00 - 16.00 h
The EMA Guidance on Medicine Shortages and Availability Issues and the European Shortages Monitoring Platform (ESMP)
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
In March CMDh published a new Q&A document to provide further guidance on the implementation of the EU Falsified Medicines Directive. The title reads "CMDh clarifications on questions received on the implementation of the Falsified Medicines Directive".
The answers confirm the very flexible, independent and phased in approach as preparation for the 2D Code and anti-tampering. How to deal with mock-ups and the different approaches in the Member States is discussed in several Q&As.
The document also indicates that the safety features can already be implemented, even if the respective variation application has not been approved. However, requests for variations should be submitted as early as possible.
The document finally confirms that everything related to the safety features on packaging has to be implemented until 9 February 2019
You can find the complete"CMDh clarifications on questions received on the implementation of the Falsified Medicines Directive" here.
Related GMP News
11.08.2026Q&A Version 22 on Safety Features for Medicinal Products
31.07.2024Report on Trends in the Falsification of Medicines
11.06.2024Serialization - Version 21 of the Q&As on Safety Features
17.01.2024Ozempic Falsification also in the US